New drug combo targets Tough-to-Treat cancer mutation
NCT ID NCT06385678
Summary
This study is testing the safety and effectiveness of a new drug called HRS-4642 when given with other cancer medications. It is for adults with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if this combination can help control the cancer and determine the best dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED KRAS G12D MUTANT SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, 200120, China
Conditions
Explore the condition pages connected to this study.